Compositions and methods for treatment of diabetic retinopathy

Abstract

The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is diagnosed with diabetic retinopathy.

1 - 63 . (canceled) 
     
     
         64 . A method of treating diabetic retinopathy in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising a compound of formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein the administering is by topical administration. 
     
     
         65 . The method of  claim 64  wherein the compound is administered in a carrier vehicle which is liquid drops, liquid wash, nebulized liquid, gel, ointment, aerosol, spray, polymer micro and nanoparticles, solution, suspension, solid, biodegradable matrix, powder, crystals, foam, or liposomes. 
     
     
         66 . The method of  claim 64 , wherein the compound is administered topically and said topical administration comprises infusion of said compound to said eyes via a device selected from the group consisting of a pump-catheter system, an insert, a continuous or selective release device, a bioabsorbable implant, a continuous or sustained release formulation, and a contact lens. 
     
     
         67 . The method according to  claim 64 , wherein said compound is administered to said subject in an amount sufficient to achieve intraocular or retinal concentrations of from about 1×10 −8  to about 1×10 −1  moles/liter. 
     
     
         68 . The method of  claim 64 , wherein said compound is administered at least once a year. 
     
     
         69 . The method of  claim 64 , wherein said compound is administered at least once a day. 
     
     
         70 . The method of  claim 64 , wherein said compound is administered at least once a week. 
     
     
         71 . The method of  claim 64 , wherein said compound is administered at least once a month. 
     
     
         72 . The method of  claim 64 , further comprising the step of determining that said subject is in need of treatment for diabetic retinopathy. 
     
     
         73 . The method of  claim 64 , further comprising administering a second therapeutic agent prior to, in combination with, at the same time, or after administration of said LFA-1 antagonist. 
     
     
         74 . The method of  claim 73 , wherein the second therapeutic agent is selected from the group consisting of antioxidants, antiinflammatory agents, antimicrobials, steroids, protein kinase C inhibitors, angiotensin converting enzyme inhibitors, antiangiogenic agents, complement inhibitors, and anti-apoptotic agents. 
     
     
         75 . The method of  claim 64 , wherein the diabetic retinopathy causes macular edema.